Thematic analysis™: A chemogenomic approach to GPCR drug discovery

Current Topics in Medicinal Chemistry

Volumn 11, Issue 15, 2011, Pages 1925-1942

  Crossley, Roger ^a   Macritchie, Jacqueline Anne ^b   Slater, Martin John ^c  

^a Crosspatch   (United Kingdom)

^b BioFocus DPI   (United Kingdom)

^c Cresset BioMolecular Discovery Ltd   (United Kingdom)

Author keywords

Chemogenomics; Drug discovery; Focused libraries; GPCR; Library design

Indexed keywords

BOMBESIN ANTAGONIST; BOMBESIN RECEPTOR; BOMBESIN RECEPTOR SUBTYPE 3; G PROTEIN COUPLED RECEPTOR; UNCLASSIFIED DRUG;

CHEMOGENOMICS; CLUSTER ANALYSIS; DRUG SELECTIVITY; GENOMICS; HUMAN; LIBRARY; MEMBRANE STRUCTURE; NONHUMAN; PHARMACOPHORE; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; THEMATIC ANALYSIS;

DRUG DESIGN; DRUG DISCOVERY; GENOMICS; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79957997272     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796391302     Document Type: Review

References (67)

1. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci., 2001, 41 (3), 856-864.
2. Jacoby, E.; Fauchère, J.-L.; Raimbaud, E.; Ollivier, S.; Michel, A.; Spedding, M. A three binding site hypothesis for the interaction of ligands with monoamine g protein-coupled receptors: implications for combinatorial ligand design. Quant. Struct.-Act. Relat., 1999, 18 (6), 561-572.
3. Jacoby, E. A novel chemogenomics knowledge-based ligand design strategy-application to G protein-coupled receptors. Quant. Struct.-Act. Relat., 2001, 20 (2), 115-123.
4. Willett, P. Similarity-based virtual screening using 2D fingerprints. Drug Discov. Today, 2006, 11 (23-24), 1046-1053.
5. Crossley, R. The design of screening libraries targeted at G-protein coupled receptors. Curr. Top. Med. Chem., 2004, 4 (6), 581-588.
6. Lipkin, M. J.; Stevens, A. P.; Livingstone, D. J.; Harris, C. J. How large does a compound screening collection need to be? Combin. Chem. High Throughput Screen., 2008, 11 (6), 482-493.
7. Harmar, A. J.; Hills, R. A.; Rosser, E. M.; Jones, M.; Buneman, O. P.; Dunbar, D. R.; Greenhill, S. D.; Hale, V. A.; Sharman, J. L.; Bonner, T. I.; Catterall, W. a.; Davenport, A. P.; Delagrange, P.; Dollery, C. T.; Foord, S. M.; Gutman, G. A.; Laudet, V.; Neubig, R. R.; Ohlstein, E. H.; Olsen, R. W.; Peters, J.; Pin, J.-P.; Ruffolo, R. R.; Searls, D. B.; Wright, M. W.; Spedding, M. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res., 2009, 37 (Database issue), D680-D685.
8. Fredriksson, R.; Lagerström, M. C.; Lundin, L.-G.; Schiöth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63 (6), 1256-1272.
9. Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev., 2000, 21 (1), 90-113.
10. Gurevich, V. V.; Gurevich, E. V. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol. Ther. 2006, 110 (3), 465-502.
11. Wise, A.; Gearing, K.; Rees, S. Target validation of G-protein coupled receptors. Drug Discov. Today, 2002, 7 (4), 235-246.
12. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le, T. I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289 (5480), 739-745.
13. Buck, E.; Bourne, H.; Wells, J. A. Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor. J. Biol. Chem., 2005, 280 (6), 4009-4012.
14. Liaw, C. W.; Grigoriadis, D.E.; Lorang, M.T.; De Souza, E.B.; Maki, R.A. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinol., 1997, 11 (13), 2048-2053.
15. Yamashita, T.; Terakita, A.; Kai, T.; Shichida, Y. Conformational change of the transmembrane helices II and IV of metabotropic glutamate receptor involved in G protein activation. J. Neurochem., 2008, 106 (2), 850-859.
16. Marie, J.; Richard, E.; Pruneau, D.; Paquet, J. L.; Siatka, C.; Larguier, R.; Ponce, C.; Vassault, P.; Groblewski, T.; Maigret, B.; Bonnafous, J. C. Control of conformational equilibria in the human B2 bradykinin receptor. Modeling of nonpeptidic ligand action and comparison to the rhodopsin structure. J. Biol. Chem., 2001, 276 (44), 41100-41111.
17. Rosenkilde, M. M.; David, R.; Oerlecke, I.; Benned-Jensen, T.; Geumann, U.; Beck-Sickinger, A. G.; Schwartz, T. W. Conformational constraining of inactive and active States of a seven transmembrane receptor by metal ion site engineering in the extracellular end of transmembrane segment V. Mol. Pharmacol., 2006, 70 (6), 1892-1901.
18. Beukers, M. W.; Kristiansen, K.; Ijzerman, A. P.; Edvardsen, O. TinyGRAP database: a bioinformatics tool to mine G-protein-coupled receptor mutant data. Trends Pharmacol. Sci., 1999, 20 (12), 475-477.
19. Ballesteros, J. A.; Deupi, X.; Olivella, M.; Haaksma, E. E.; Pardo, L. Serine and threonine residues bend alpha-helices in the chi(1) = g(-) conformation. Biophys. J., 2000, 79 (5), 2754-2760.
20. Deupi, X.; Olivella, M.; Govaerts, C.; Ballesteros, J. A.; Campillo, M.; Pardo, L. Ser and Thr residues modulate the conformation of pro-kinked transmembrane alpha-helices. Biophys. J., 2004, 86 (1 Pt 1), 105-115.
21. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 2007, 318 (5854), 1258-1265.
22. Rasmussen, S. G. F.; Choi, H.-J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R. P.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F. X.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature, 2007, 450(7168), 383-387.
23. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G. W.; Tate, C. G.; Schertler, G. F. X. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 2008, 454(7203), 486-491.
24. Jaakola, V.-P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y. T.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 2008, 322(5905), 1211-1217.
25. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci., 1995, 25, 366-428.
26. Ballesteros, J. A.; Jensen, A. D.; Liapakis, G.; Rasmussen, S. G.; Shi, L.; Gether, U.; Javitch, J. A. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem., 2001, 276(31), 29171-29177.
27. Tan, E. S.; Groban, E. S.; Jacobson, M. P.; Scanlan, T. S. Toward deciphering the code to aminergic G protein-coupled receptor drug design. Chem. Biol, 2008, 15(4), 343-353.
28. Nygaard, R.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Schwartz, T. W. Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol. Sci., 2009, 30 (5), 249-259.
29. Rhee, M. H.; Nevo, I.; Bayewitch, M. L.; Zagoory, O.; Vogel, Z. Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor. J. Neurochem., 2000, 75(6), 2485-2491.
30. Kyte, J.; Doolittle, R. F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol., 1982, 157 (1), 105-132.
31. Campagne, F.; Jestin, R.; Reversat, J. L.; Bernassau, J. M.; Maigret, B. Visualisation and integration of G protein-coupled receptor related information help the modelling: description and applications of the Viseur program. J. Comput. Aided Mol. Des., 1999, 13 (6), 625-643.
32. Klabunde, T.; Evers, A. GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects. Chembiochem., 2005, 6 (5), 876-889.
33. Schwartz, T. W. Locating ligand-binding sites in 7TM receptors by protein engineering. Curr. Opin. Biotechnol, 1994, 5 (4), 434-444.
34. Chan, A. W.; Laskowski, R. A.; Selwood, D. L. Chemical fragments that hydrogen bond to Asp, Glu, Arg, and His side chains in protein binding sites. J. Med. Chem., 2010, 53 (8), 3086-3094.
35. Carter, P. H.; Liu, R. Q.; Foster, W. R.; Tamasi, J. A.; Tebben, A. J.; Favata, M.; Staal, A.; Cvijic, M. E.; French, M. H.; Dell, V.; Apanovitch, D.; Lei, M.; Zhao, Q.; Cunningham, M.; Decicco, C. P.; Trzaskos, J. M.; Fey en, J. H. Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe. Proc. Natl. Acad. Sci. USA, 2007, 104 (16), 6846-6851.
36. McDonald, I. M.; Austin, C; Buck, I. M.; Dunstone, D. J.; Gaffen, J.; Griffin, E.; Harper, E. A.; Hull, R. A.; Kalindjian, S. B.; Linney, I. D.; Low, C. M.; Patel, D.; Pether, M. J.; Raynor, M.; Roberts, S. P.; Shaxted, M. E.; Spencer, J.; Steel, K. I.; Sykes, D. A.; Wright, P. T.; Xun, W., Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists. J. Med. Chem., 2007, 50 (20), 4789-4792.
37. O'Dowd, B. F.; Scheideler, M. A.; Nguyen, T.; Cheng, R.; Rasmussen, J. S.; Marchese, A.; Zastawny, R.; Heng, H. H.; Tsui, L. C; Shi, X. The cloning and chromosomal mapping of two novel human opioid-somatostatin-like receptor genes, GPR7 and GPR8, expressed in discrete areas of the brain. Genomics, 1995, 28 (1), 84-91.
38. Zaveri, N.; Jiang, F.; Olsen, C; Polgar, W.; Toll, L. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP. AAPS J., 2005, 7 (2), E345-352.
39. Graffner, N. M.; Barf, T.; Mott, A. Preparation of beta-carboline derivatives as GHSR modulators. 2006.
40. Barker, E.; Jenmalm, J. A.; Nordling, E.; Proud, A.; Slater, M.; Weber, M. Preparation of 4H-spiro[1,3]benzodioxine-2,4'-piperidine derivatives and related compounds. 2006.
41. Brandt, P.; Bremberg, U.; Crossley, R.; Graffner, N. M.; Jenmalm, J. A.; Ringberg, E.; Ward, T. Preparation of spiro(p-carbolinepyrrolidines) and related compounds as growth hormone secretagogue receptor (GHSR) antagonists. 2005.
42. Berthold, M.; Crossley, R.; Ward, T. Synthesis of imidazo[1,5-a]pyridine or imidazo[1,5-a]piperidine derivatives and their use in treatment of 5-HT2A receptor-related disorders. 2005.
43. Crossley, R.; Ward, T.; Berthold, M. Preparation of 4-piperidinecarboxamide derivatives and their use in the treatment against 5-HT2A receptor-related disorders. 2005.
44. Jones, G. P.; MacRitchie, J. A.; Slater, M. J. A preparation of library of 4-piperidylcarboxamide derivatives capable of binding to a G-protein coupled receptor. 2005.
45. Barker, E.; Proud, A.; Slater, M. Preparation of spiro[1,3-benzodioxine-2,4'-piperidine] library capable of binding to a G-protein coupled receptor. 2004.
46. Ward, T.; Crossley, R.; Macritchie, J. A. Preparation of unsaturated heterocyclic or carbocyclic fused imidazole derivative based chem. screening library for identification of ligands capable of binding to G-protein coupled receptors. 2004.
47. Jones, G. P.; Parsy, C.; Macritchie, J. A. Preparation of substituted indazole derivatives capable of binding to G-protein coupled receptors. 2004.
48. Jones, G. P.; Hardy, D.; Macritchie, J. A.; Slater, M. J. Preparation of 2,3-substituted pyrazine derivatives capable of binding to G-protein coupled receptors. 2004.
49. Ward, T.; Crossley, R.; Slater, M. J. Preparation of spiroheterocycles and imidazopyridine derivative based chem. screening library for identification of ligands capable of binding to G-protein coupled receptors. 2004.
50. Ward, T.; Crossley, R. Preparation of tetrahydrospiro(beta-carboline-1,4-piperidine) derivatives and related compounds to form a chem. Screening library for identification of ligands capable of binding to G-protein coupled receptors. 2004.
51. Ward, T.; Crossley, R. Preparation of N-(aminocarbonyl)-piperidine-4-carboxamide derivative based chem. Screening library for identification of ligands capable of binding to G-protein coupled receptors. 2004.
52. Crosignani, S.; Page, P.; Missotten, M.; Colovray, V.; Cleva, C.; Arrighi, J. F.; Atherall, J.; Macritchie, J.; Martin, T.; Humbert, Y.; Gaudet, M.; Pupowicz, D.; Maio, M.; Pittet, P. A.; Golzio, L.; Giachetti, C.; Rocha, C.; Bernardinelli, G.; Filinchuk, Y.; Scheer, A.; Schwarz, M. K.; Chollet, A. Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J. Med. Chem., 2008, 51 (7), 2227-2243.
53. Jensen, A. D.; Guarnieri, F.; Rasmussen, S. G.; Asmar, F.; Ballesteros, J. A.; Gether, U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J. Biol. Chem., 2001, 276 (12), 9279-9290.
54. Ward, T. J.; Crossley, R.; Slater, M. J. Preparation of imidazopyridine derivatives as BRS-3 antagonists. 2005.
55. Barker, E.; Crossley, R. Indazole derivatives which interact with the G protein-coupled receptor family, and their preparation, pharmaceutical compositions, and use against BRS-3 receptor-related disorders. 2005.
56. Ohki-Hamazaki, H.; Watase, K.; Yamamoto, K.; Ogura, H.; Yamano, M.; Yamada, K.; Maeno, H.; Imaki, J.; Kikuyama, S.; Wada, E.; Wada, K. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature, 1997, 390 (6656), 165-169.
57. Yamada, K.; Wada, E.; Imaki, J.; Ohki-Hamazaki, H.; Wada, K. Hyperresponsiveness to palatable and aversive taste stimuli in genetically obese (bombesin receptor subtype-3-deficient) mice. Physiol. Behav., 1999, 66 (5), 863-867.
58. Toi-Scott, M.; Jones, C. L.; Kane, M. A. Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer, 1996, 15 (3), 341-354.
59. Fathi, Z.; Corjay, M. H.; Shapira, H.; Wada, E.; Benya, R.; Jensen, R.; Viallet, J.; Sausville, E. A.; Battey, J. F., BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J. Biol. Chem., 1993, 268 (8), 5979-5984.
60. Reubi, J. C.; Wenger, S.; Schmuckli-Maurer, J.; Schaer, J. C.; Gugger, M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin. Cancer Res., 2002, 8 (4), 1139-1146.
61. Smart, D.; Strijbos, P. Bombesin receptor subtype 3 polynucleo-tides, polypeptides and ligands for use in treating neurological disorders. 2001.
62. Crossley, R.; Slater, M. J.; Jacoby, E. A reductionist approach to chemogenomics in the design of drug molecules and focused libraries. World Scientific Publishing: 2006; pp 85-108.
63. Heilker, R.; Wolff, M.; Tautermann, C. S.; Bieler, M. G-protein-coupled receptor-focused drug discovery using a target class platform approach. Drug Discov. Today, 2009, 14 (5-6), 231-240.
64. Gloriam, D. E.; Foord, S. M.; Blaney, F. E.; Garland, S. L. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J. Med. Chem., 2009, 52 (14), 4429-4442.
65. Rognan, D. Chemogenomic approaches to rational drug design. Br. J. Pharmacol. 2007, 152 (1), 38-52.
66. Congreve, M.; Marshall, F. The impact of GPCR structures on pharmacology and structure-based drug design. Br. J. Pharmacol., 2010, 159 (5), 986-996.
67. Yin, H.; Chu, A.; Li, W.; Wang, B.; Shelton, F.; Otero, F.; Nguyen, D. G.; Caldwell, J. S.; Chen, Y. A. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J. Biol. Chem., 2009, 284 (18), 12328-12338.